Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Mannitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.53 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL27352819 | 1.00 | USP2 (0.60) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Adonitol SCHEMBL27529790 | 0.95 | USP2 (0.54) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Mannitol SCHEMBL9400683 | 0.93 | USP2 (0.54) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Gluconic Acid SCHEMBL28069153 | 0.89 | PDE4A (0.79) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Gluconic Acid SCHEMBL5805996 | 0.89 | PDE4A (0.79) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Gluconic Acid SCHEMBL17965938 | 0.87 | PDE4A (0.76) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Gluconic Acid SCHEMBL1070308 | 0.87 | PDE4A (0.76) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Gluconic Acid SCHEMBL29379109 | 0.87 | PDE4A (0.76) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Demannose SCHEMBL2293273 | 0.85 | USP2 (0.47) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| Demannose SCHEMBL9818467 | 0.85 | USP2 (0.47) | USP2SLCO1B1PDE4ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-219461076-U | Disposable anal fistula mirror | 福建智德医疗科技有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230192832-A1 | PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB | Shanghai Henlius Biotech, Inc. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4115903-A1 | PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB | Shanghai Henlius Biotech, Inc. (CN) | 2023-01-11 | — | — | EP | disclosed |
| CN-115066262-A | Pharmaceutical formulation comprising bevacizumab | 上海复宏汉霖生物技术股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-107088224-B | Lyophilized formulation of human FGF21 | 温州医科大学 | 2020-06-26 | — | — | CN | disclosed |
| EP-3532036-A1 | PROCESS FOR ISOLATING AND LYOPHILIZING EXTRACELLULAR VESICLES | Pharmaexceed S.r.l. (IT) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018078524-A1 | PROCESS FOR ISOLATING AND LYOPHILIZING EXTRACELLULAR VESICLES | PHARMAEXCEED S.R.L. (IT) | 2018-05-03 | — | — | WO | disclosed |
| EP-3256160-A1 | STABLE LIQUID FORMULATION FOR MONOCLONAL ANTIBODIES | SANOFI (FR) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016128564-A1 | STABLE LIQUID FORMULATION FOR MONOCLONAL ANTIBODIES | SANOFI (FR) | 2016-08-18 | — | — | WO | disclosed |
| EP-3046572-A1 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20010055583-A1 | Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby | QUADRANT DRUG DELIVERY LIMITED (GB) | 2001-12-27 | — | — | US | disclosed |
| CN-1280511-A | A one dose syringe, comprising a freeze-dried protein composition, for administering of a volume less than 0.5ml | PHARMACIA & UPJOHN AB (SE) | 2001-01-17 | — | — | CN | disclosed |
| EP-0904293-A1 | AN INTERLEUKIN-5 ANTAGONIST | BresaGen Limited (AU) | 1999-03-31 | — | — | EP | disclosed |
| EP-0876155-A1 | HIGHLY CONCENTRATED, LYOPHILIZED, AND LIQUID FACTOR IX FORMULATIONS | GENETICS INSTITUTE, INC. (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997045448-A1 | AN INTERLEUKIN-5 ANTAGONIST | BRESAGEN LIMITED (AU) | 1997-12-04 | — | — | WO | disclosed |
| CN-1156967-A | Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby | QUADRANT HOLDINGS CAMBRIDGE (GB) | 1997-08-13 | — | — | CN | disclosed |
| WO-1997026909-A1 | HIGHLY CONCENTRATED, LYOPHILIZED, AND LIQUID FACTOR IX FORMULATIONS | GENETICS INSTITUTE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997026005-A1 | IGF-I IN COMBINATION WITH HYPOGLYCEMICS FOR TREATMENT OF DIABETES | GENENTECH, INC. (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0762897-A1 | METHOD OF PREVENTING AGGREGATION OF VARIOUS SUBSTANCES UPON REHYDRATION OR THAWING AND COMPOSITIONS OBTAINED THEREBY | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033488-A1 | METHOD OF PREVENTING AGGREGATION OF VARIOUS SUBSTANCES UPON REHYDRATION OR THAWING AND COMPOSITIONS OBTAINED THEREBY | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1995-12-14 | — | — | WO | disclosed |